查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1463881

标靶定序市场 - 全球产业规模、份额、趋势、竞争、机会和预测，按产品类型、目标富集方法、目标捕获类型、应用、最终用户、地区、竞争细分，2019-2029F

Targeted Sequencing Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, Segmented By Product Type, By Target Enrichment Method, By Target Capture Type, By Application, By End Users, By Region, By Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2023 年全球标靶定序市场估值为35.1 亿美元，预计到2029 年预测期内将强劲成长，复合年增长率为11.02%。级增长技术以及对精准医疗和个人化医疗解决方案不断增长的需求。标靶定序，也称为次世代定序 (NGS)，能够精确检查基因组内的特定兴趣区域，使研究人员和临床医生能够有效识别与各种疾病相关的变异、突变和生物标记。该技术透过提供高通量、经济高效且准确的定序解决方案，彻底改变了生物医学研究、临床诊断和药物发现过程。

推动全球靶向测序市场扩张的关键因素包括遗传性疾病和癌症发病率的增加、伴随诊断的日益采用以及基因组学研究和开发投资的增加。此外，标靶定序与转录组学、表观基因组学和代谢组学等其他组学技术的整合，为全面的分子分析和更深入了解疾病背后的生物学机制开闢了新途径。

市场参与者不断创新，以提高定序准确性、缩短週转时间并降低定序成本，使标靶定序在不同的应用和环境中变得更加容易和可行。此外，基于云端的定序平台和生物资讯解决方案的出现正在促进资料管理、分析和解释，进一步推动市场成长。儘管成长前景巨大，但资料隐私问题、报销问题和资料解释的复杂性等挑战仍然存在。儘管如此，学术界、工业界和监管机构之间的合作，加上持续的技术进步，预计将推动全球靶向测序市场向前发展，在可预见的未来实现更精确的诊断、个性化治疗并改善患者的治疗结果。

主要市场驱动因素

遗传性疾病和癌症族群的发生率不断增加

定序技术的进步

基因组学研究和开发投资不断增加

主要市场挑战

监管障碍

数据分析与解释

主要市场趋势

与组学技术集成

基于云端的定序平台和生物资讯解决方案的出现

细分市场洞察

产品类型见解

目标富集方法见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球标靶定序市场展望

  • 市场规模预测
    • 按价值
  • 市占率预测
    • 依产品类型（试剂盒/面板及检测、仪器及其他）
    • 依目标富集方法（扩增子定序、杂交捕获等）
    • 按目标捕获类型（靶向 DNA 测序、靶向 RNA 测序等）
    • 依应用（肿瘤、传染病、心血管疾病、生殖健康、罕见疾病、神经系统疾病、遗传性疾病等）
    • 按最终用户（学术和研究机构、製药和生物技术公司、诊断临床实验室等）
    • 按公司划分 (2023)
    • 按地区
  • 市场地图

第 6 章：北美标靶定序市场展望

  • 市场规模预测
    • 按价值
  • 市占率预测
    • 依产品类型
    • 透过目标富集方法
    • 按目标捕获类型
    • 按申请
    • 由最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 7 章：欧洲标靶定序市场展望

  • 市场规模预测
    • 按价值
  • 市占率预测
    • 依产品类型
    • 透过目标富集方法
    • 按目标捕获类型
    • 按申请
    • 由最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章：亚太地区标靶定序市场展望

  • 市场规模预测
    • 按价值
  • 市占率预测
    • 依产品类型
    • 透过目标富集方法
    • 按目标捕获类型
    • 按申请
    • 由最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第 9 章：南美洲标靶定序市场展望

  • 市场规模预测
    • 按价值
  • 市占率预测
    • 依产品类型
    • 透过目标富集方法
    • 按目标捕获类型
    • 按申请
    • 由最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东与非洲定向定序市场展望

  • 市场规模预测
    • 按价值
  • 市占率预测
    • 依产品类型
    • 透过目标富集方法
    • 按目标捕获类型
    • 按申请
    • 由最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势发展

  • 併购（如有）
  • 产品发布（如有）
  • 最近的发展

第 13 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • MGI Tech Co., Ltd
  • GENEWIZ Inc
  • Agilent Technologies, Inc.
  • Daicel Arbor Biosciences
  • Danaher Corporation
  • Illumina, Inc.
  • LGC Biosearch Technologies
  • Pacific Biosciences of California Inc
  • CD Genomics
  • F. Hoffmann-La Roche Ltd

第 15 章：策略建议

第 16 章：关于我们免责声明

简介目录
Product Code: 14954

Global Targeted Sequencing Market was valued at USD 3.51 Billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 11.02% through 2029. The Global Targeted Sequencing Market has witnessed exponential growth in recent years, driven by advancements in sequencing technologies and a burgeoning demand for precision medicine and personalized healthcare solutions. Targeted sequencing, also known as next-generation sequencing (NGS), enables the precise examination of specific regions of interest within the genome, allowing researchers and clinicians to efficiently identify variations, mutations, and biomarkers associated with various diseases. This technology has revolutionized biomedical research, clinical diagnostics, and drug discovery processes by offering high-throughput, cost-effective, and accurate sequencing solutions.

Key factors fueling the expansion of the global targeted sequencing market include increasing incidences of genetic disorders and cancer, growing adoption of companion diagnostics, and rising investments in genomics research and development. Moreover, the integration of targeted sequencing with other omics technologies such as transcriptomics, epigenomics, and metabolomics is opening new avenues for comprehensive molecular profiling and deeper insights into biological mechanisms underlying diseases.

Market players are continuously innovating to enhance sequencing accuracy, reduce turnaround times, and lower sequencing costs, thereby making targeted sequencing more accessible and feasible across diverse applications and settings. Additionally, the emergence of cloud-based sequencing platforms and bioinformatics solutions is facilitating data management, analysis, and interpretation, further driving market growth. Despite the immense growth prospects, challenges such as data privacy concerns, reimbursement issues, and complexity in data interpretation remain pertinent. Nonetheless, collaborations between academia, industry, and regulatory bodies, coupled with ongoing technological advancements, are expected to propel the global targeted sequencing market forward, enabling more precise diagnostics, personalized treatments, and improved patient outcomes in the foreseeable future.

Key Market Drivers

Increasing Incidences of Genetic Disorders and Cancer Population

The increasing incidences of genetic disorders and cancer within the global population are significant factors driving the growth of the targeted sequencing market. Genetic disorders, characterized by mutations or abnormalities in an individual's DNA, encompass a wide range of conditions, including cystic fibrosis, Huntington's disease, and muscular dystrophy. According to the World Health Organization (WHO), genetic disorders affect millions of people worldwide, contributing to morbidity, mortality, and healthcare costs. As advancements in medical genetics enable the identification of disease-causing mutations, there is a growing demand for precise and comprehensive sequencing technologies to facilitate genetic testing, diagnosis, and genetic counseling.

Cancer, a complex genetic disease characterized by the uncontrolled growth and spread of abnormal cells, remains a major public health challenge globally. The incidence of cancer continues to rise, fueled by various factors such as aging populations, lifestyle changes, environmental exposures, and genetic predispositions. According to the International Agency for Research on Cancer (IARC), the global burden of cancer is projected to increase substantially in the coming decades, posing significant challenges to healthcare systems worldwide. Targeted sequencing plays a crucial role in oncology by enabling the identification of somatic mutations, copy number variations, and gene fusions associated with cancer development and progression.

In the context of precision oncology, targeted sequencing-based approaches such as tumor profiling and liquid biopsy hold immense promise for guiding treatment decisions, predicting treatment responses, and monitoring disease progression. By analyzing the genomic landscape of tumors, clinicians can identify actionable mutations and molecular targets for targeted therapies, immunotherapies, and personalized treatment regimens. Additionally, targeted sequencing facilitates the development of companion diagnostics, enabling the selection of appropriate therapies based on the individual's genetic profile. As the prevalence of cancer and genetic disorders continues to rise, there is an escalating demand for advanced genomic technologies capable of delivering accurate and actionable insights into disease etiology, prognosis, and therapeutic responses, thereby driving the growth of the global targeted sequencing market.

Advancements in Sequencing Technologies

Advancements in sequencing technologies have been pivotal in driving the exponential growth of the global targeted sequencing market. Over the past few decades, the field of genomics has witnessed remarkable progress, fueled by continuous innovations in sequencing platforms, chemistry, and bioinformatics tools. These advancements have revolutionized our ability to decode the genetic blueprint of organisms with unprecedented speed, accuracy, and cost-effectiveness.

Next-generation sequencing (NGS) technologies have been at the forefront of this revolution, enabling researchers and clinicians to sequence DNA and RNA molecules at an unprecedented scale. These platforms, which include Illumina's HiSeq, NovaSeq, and MiSeq systems, as well as platforms from other leading manufacturers such as Thermo Fisher Scientific, Oxford Nanopore Technologies, and Pacific Biosciences, offer high-throughput sequencing capabilities, allowing the simultaneous analysis of thousands to millions of DNA fragments in parallel.

Advancements in sequencing chemistry and library preparation methods have improved sequencing accuracy, read lengths, and coverage uniformity, thereby enhancing the resolution and reliability of sequencing data. For instance, the development of reversible terminator chemistry and nanopore-based sequencing technologies has enabled longer read lengths, reduced error rates, and enhanced base-calling accuracy, enabling researchers to capture complex genomic structures and detect rare genetic variants with greater sensitivity.

The commercialization of third-generation sequencing technologies, such as single-molecule real-time (SMRT) sequencing and nanopore sequencing, has democratized access to long-read sequencing capabilities, offering insights into genomic regions that were previously inaccessible or challenging to sequence. These technologies are particularly valuable for resolving repetitive regions, structural variants, and complex genomic rearrangements, which are often missed or misinterpreted by short-read sequencing methods.

Rising Investments in Genomics Research and Development

The global targeted sequencing market is experiencing a surge in growth driven by rising investments in genomics research and development (RD). Governments, academic institutions, and private companies are increasingly recognizing the transformative potential of genomics in advancing biomedical research, clinical diagnostics, and drug discovery. As a result, significant resources are being allocated to support genomics initiatives aimed at unraveling the complexities of the human genome and its role in health and disease.

One of the key drivers of increased investments in genomics RD is the growing realization of the value of genomic information in understanding disease mechanisms, identifying therapeutic targets, and developing personalized treatment strategies. Genomics research has led to groundbreaking discoveries in various fields, including cancer biology, rare genetic disorders, infectious diseases, and complex traits. By leveraging targeted sequencing technologies, researchers can precisely interrogate specific genomic regions associated with disease susceptibility, drug metabolism, and treatment response, thereby accelerating the pace of biomedical innovation.

The advent of large-scale genomic initiatives, such as the Human Genome Project, the Cancer Genome Atlas, and the UK Biobank, has catalyzed collaborative efforts to generate comprehensive genomic datasets on a global scale. These initiatives have facilitated data sharing, standardization, and harmonization, enabling researchers to conduct large-scale genomic studies and identify genetic variants underlying complex diseases and traits.

In addition to academic and governmental investments, there has been a surge in private sector investment in genomics RD, driven by the promise of commercial opportunities in precision medicine, molecular diagnostics, and biopharmaceuticals. Biotechnology companies, pharmaceutical firms, and venture capital investors are actively funding genomic startups and innovation hubs focused on developing novel sequencing technologies, bioinformatics solutions, and genomic-based therapeutics.

Key Market Challenges

Regulatory Hurdles

Another significant challenge facing the global targeted sequencing market is regulatory uncertainty and complexity. As targeted sequencing technologies are used in clinical diagnostics, pharmaceutical development, and agricultural genomics, they are subject to stringent regulatory requirements imposed by health authorities and governing bodies worldwide.

Navigating the regulatory landscape can be particularly daunting for companies seeking to commercialize targeted sequencing products and services. Compliance with regulations such as the U.S. Food and Drug Administration's (FDA) approval process for in vitro diagnostic devices (IVDs) or the European Union's in vitro diagnostic regulation (IVDR) necessitates substantial investments in time, resources, and expertise. Moreover, regulatory frameworks vary across regions, further complicating market entry and expansion strategies.

The lack of harmonization and standardized guidelines for targeted sequencing-based assays poses challenges for market players operating on a global scale. Regulatory delays, uncertainties, and compliance costs can impede innovation and market access, stifling growth opportunities and hampering the adoption of targeted sequencing technologies in clinical settings and beyond.

To overcome regulatory hurdles, stakeholders must engage proactively with regulatory agencies, stay abreast of evolving requirements, and prioritize compliance and quality assurance throughout the product development lifecycle. Collaboration between industry stakeholders, policymakers, and regulatory bodies is essential to streamline regulatory processes, foster innovation, and ensure patient safety and product efficacy.

Data Analysis and Interpretation

While sequencing technologies have made significant strides in generating vast amounts of genomic data, extracting meaningful insights from this data remains a formidable task. The complexity of genomic data, coupled with the heterogeneity of biological systems, poses challenges for accurate variant calling, annotation, and interpretation.

The integration of multi-omics data, such as transcriptomics, epigenomics, and proteomics, adds another layer of complexity to data analysis workflows. Bioinformatics tools and algorithms play a crucial role in processing, analyzing, and interpreting genomic data, but their efficacy depends on factors such as data quality, sample heterogeneity, and computational resources.

The shortage of skilled bioinformaticians and data scientists capable of handling large-scale genomic datasets poses a bottleneck for market growth. As the volume and complexity of genomic data continue to increase, there is a pressing need for user-friendly, scalable, and interoperable bioinformatics solutions to facilitate data analysis and interpretation across diverse applications. Addressing the challenges associated with data analysis and interpretation requires collaborative efforts between academia, industry, and government agencies to develop robust bioinformatics tools, standardize data formats, and promote data sharing and collaboration. Investing in workforce development and training programs can also help bridge the gap in bioinformatics expertise and empower researchers and clinicians to harness the full potential of targeted sequencing technologies for precision medicine and scientific discovery.

Key Market Trends

Integration with Omics Technologies

The integration of targeted sequencing with other omics technologies is playing a pivotal role in boosting the global targeted sequencing market. Omics technologies encompass various disciplines, including genomics, transcriptomics, proteomics, metabolomics, and epigenomics, each offering unique insights into the molecular landscape of biological systems. By integrating targeted sequencing with omics technologies, researchers can achieve a more comprehensive understanding of the complex interactions between genes, proteins, metabolites, and epigenetic modifications, thereby unraveling the underlying mechanisms of diseases and facilitating precision medicine approaches.

Integrating targeted sequencing with omics technologies is the ability to perform multi-dimensional molecular profiling, which enables researchers to capture a holistic view of biological processes at the molecular level. For example, by combining targeted sequencing with transcriptomics, researchers can correlate genetic mutations with changes in gene expression, allowing for the identification of key regulatory pathways and potential therapeutic targets. Similarly, integrating targeted sequencing with proteomics and metabolomics enables the characterization of protein-protein interactions, metabolic pathways, and biomarker discovery, providing valuable insights into disease mechanisms and treatment responses.

The integration of targeted sequencing with omics technologies enhances the sensitivity and specificity of molecular profiling, enabling the detection of rare genetic variants, low-abundance transcripts, and subtle changes in protein expression or metabolite levels. This is particularly important in the context of cancer diagnostics and personalized medicine, where accurate identification of actionable mutations and biomarkers is crucial for guiding treatment decisions and predicting therapeutic outcomes.

The integration of targeted sequencing with omics technologies is driving innovation in computational biology and bioinformatics, as researchers develop advanced algorithms and analytical pipelines for integrating and interpreting multi-omics data sets. These bioinformatics solutions enable researchers to extract meaningful insights from complex data, identify biologically relevant patterns and associations, and generate actionable hypotheses for further investigation.

Emergence of Cloud-Based Sequencing Platforms and Bioinformatics Solutions

The emergence of cloud-based sequencing platforms and bioinformatics solutions is playing a crucial role in boosting the global targeted sequencing market. Cloud computing technologies offer scalable, cost-effective, and secure solutions for storing, processing, and analyzing vast amounts of sequencing data, thereby overcoming the computational challenges associated with genomic research and clinical diagnostics. By leveraging cloud-based sequencing platforms and bioinformatics solutions, researchers and clinicians can accelerate data analysis, interpretation, and knowledge discovery, leading to significant advancements in precision medicine and personalized healthcare.

Cloud-based sequencing platform's ability to provide on-demand access to high-performance computing resources, enabling researchers to analyze large-scale sequencing datasets with unprecedented speed and efficiency. This is particularly important in the context of targeted sequencing, where researchers often need to analyze thousands to millions of genomic regions across multiple samples simultaneously. Cloud-based platforms such as Amazon Web Services (AWS), Google Cloud Platform (GCP), and Microsoft Azure offer powerful computational resources, advanced data management tools, and scalable storage solutions tailored to the needs of genomic research and analysis.

Cloud-based sequencing platforms facilitate collaboration and data sharing among researchers and institutions worldwide, enabling seamless integration of multi-omics data sets and enabling large-scale collaborative projects. By providing centralized access to genomic data and analysis pipelines, cloud-based platforms streamline workflows, reduce data silos, and foster interdisciplinary collaborations, thereby accelerating scientific discovery and innovation.

Furthermore, the emergence of cloud-based bioinformatics solutions is democratizing access to advanced analytical tools and algorithms for processing, analyzing, and interpreting sequencing data. These bioinformatics solutions offer user-friendly interfaces, customizable workflows, and pre-configured pipelines for performing a wide range of genomic analyses, from variant calling and annotation to pathway analysis and integrative genomics. By eliminating the need for costly hardware infrastructure and specialized expertise, cloud-based bioinformatics solutions empower researchers and clinicians to leverage state-of-the-art computational resources and bioinformatics tools for genomics research and clinical diagnostics.

Segmental Insights

Product Type Insights

Based on the product type, the kits/panels and assays segment emerged as the dominant segment in the Global Targeted Sequencing Market in 2023.the availability of pre-designed panels and assay kits tailored for specific genomic regions or disease areas has simplified the targeted sequencing workflow, making it more accessible to researchers and clinicians. These kits typically include all the necessary reagents, primers, and protocols required for targeted sequencing experiments, thereby reducing the complexity and time required for experimental setup and optimization.Advancements in sequencing chemistry, library preparation methods, and bioinformatics algorithms have enhanced the sensitivity, specificity, and accuracy of targeted sequencing assays, further driving their adoption in research and clinical settings. These technological advancements have enabled researchers to detect low-frequency mutations, rare genetic variants, and structural rearrangements with greater confidence, expanding the utility of targeted sequencing for a wide range of applications.

Target Enrichment Method Insights

Based on the target enrichment method, the hybridization capture segment emerged as the dominant segment in the global targeted sequencing market in 2023.Hybridization Capture offers a versatile and flexible approach to target enrichment, enabling researchers to selectively capture and amplify specific genomic regions of interest. This method utilizes custom-designed probes or baits complementary to the target sequences, allowing for highly specific and efficient capture of DNA or RNA molecules from complex genomic or transcriptomic samples. The flexibility of Hybridization Capture allows researchers to design custom panels targeting genes, exons, or genomic regions relevant to their research interests or clinical applications.

Hybridization Capture exhibits high sensitivity and specificity, enabling the detection of low-frequency mutations, rare genetic variants, and structural rearrangements with exceptional accuracy. By selectively enriching the desired target sequences, Hybridization Capture reduces the complexity of sequencing libraries, thereby improving sequencing depth and coverage uniformity, which are critical for robust variant detection and downstream data analysis.

Regional Insights

North America emerged as the dominant region in the Global Targeted Sequencing Market in 2023, holding the largest market share.North America boasts a robust infrastructure for genomics research and development, with leading academic institutions, research centers, and biotechnology hubs driving innovation in sequencing technologies and applications. The region is home to renowned genomics institutes, such as the Broad Institute, the National Institutes of Health (NIH), and the Jackson Laboratory, which spearhead groundbreaking research initiatives and collaborative projects focused on understanding the genetic basis of diseases and advancing precision medicine.Furthermore, increasing incidences of genetic disorders, cancer, and chronic diseases in North America, coupled with growing demand for personalized medicine and precision oncology, have contributed to the widespread adoption of targeted sequencing technologies across clinical and research settings.

Key Market Players

MGI Tech Co., Ltd

GENEWIZ Inc

Agilent Technologies, Inc.

Daicel Arbor Biosciences

Danaher Corporation

Illumina, Inc.

LGC Biosearch Technologies

Pacific Biosciences of California Inc

CD Genomics

F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Targeted Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Targeted Sequencing Market,By Product Type:

  • Kits/Panels and Assays
  • Instruments
  • Other

Targeted Sequencing Market,By Target Enrichment Method:

  • Amplicon Sequencing
  • Hybridization Capture
  • Others

Targeted Sequencing Market,By Target Capture Type:

  • Targeted DNA Sequencing
  • Targeted RNA Sequencing
  • Others

Targeted Sequencing Market,By End Users:

  • Academic and Research Institution
  • Pharmaceutical and Biotech Companies
  • Diagnostic Clinical Laboratories
  • Other

Targeted Sequencing Market,By Application:

  • Oncology
  • Infectious Diseases
  • Cardiovascular Diseases
  • Reproductive Health
  • Rare Diseases
  • Neurological Disorders
  • Hereditary Diseases
  • Others

Targeted Sequencing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Targeted Sequencing Market.

Available Customizations:

Global Targeted Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

  • 1.1.Market Definition
  • 1.2.Scope of the Market
    • 1.2.1.Markets Covered
    • 1.2.2.Years Considered for Study
    • 1.2.3.Key Market Segmentations

2.Research Methodology

  • 2.1.Objective of the Study
  • 2.2.Baseline Methodology
  • 2.3.Key Industry Partners
  • 2.4.Major Association and Secondary Sources
  • 2.5.Forecasting Methodology
  • 2.6.Data Triangulation Validation
  • 2.7.Assumptions and Limitations

3.Executive Summary

  • 3.1.Overview of the Market
  • 3.2.Overview of Key Market Segmentations
  • 3.3.Overview of Key Market Players
  • 3.4.Overview of Key Regions/Countries
  • 3.5.Overview of Market Drivers, Challenges, and Trends

4.Voice of Customer

5.Global Targeted Sequencing Market Outlook

  • 5.1.Market Size Forecast
    • 5.1.1.By Value
  • 5.2.Market Share Forecast
    • 5.2.1.By Product Type (Kits/Panels and Assays, Instruments and Other)
    • 5.2.2.By Target Enrichment Method (Amplicon Sequencing, Hybridization Capture, and others)
    • 5.2.3.By Target capture type (Targeted DNA Sequencing, Targeted RNA Sequencing and Others)
    • 5.2.4.By Application (Oncology, Infectious Diseases, Cardiovascular Diseases, Reproductive Health, Rare Diseases, Neurological Disorders, Hereditary Diseases and Others)
    • 5.2.5.By End Users (Academic and Research Institution, Pharmaceutical and Biotech Companies, Diagnostic Clinical Laboratories and Other)
    • 5.2.6.By Company (2023)
    • 5.2.7.By Region
  • 5.3.Market Map

6.North America Targeted Sequencing Market Outlook

  • 6.1.Market Size Forecast
    • 6.1.1.By Value
  • 6.2.Market Share Forecast
    • 6.2.1.By Product Type
    • 6.2.2.By Target Enrichment Method
    • 6.2.3.By Target capture type
    • 6.2.4.By Application
    • 6.2.5.By End Users
    • 6.2.6.By Country
  • 6.3.North America: Country Analysis
    • 6.3.1.United States Targeted Sequencing Market Outlook
      • 6.3.1.1.Market Size Forecast
        • 6.3.1.1.1.By Value
      • 6.3.1.2.Market Share Forecast
        • 6.3.1.2.1.By Product Type
        • 6.3.1.2.2.By Target Enrichment Method
        • 6.3.1.2.3.By Target capture type
        • 6.3.1.2.4.By Application
        • 6.3.1.2.5.By End Users
    • 6.3.2.Mexico Targeted Sequencing Market Outlook
      • 6.3.2.1.Market Size Forecast
        • 6.3.2.1.1.By Value
      • 6.3.2.2.Market Share Forecast
        • 6.3.2.2.1.By Product Type
        • 6.3.2.2.2.By Target Enrichment Method
        • 6.3.2.2.3.By Target capture type
        • 6.3.2.2.4.By Application
        • 6.3.2.2.5.By End Users
    • 6.3.3.Canada Targeted Sequencing Market Outlook
      • 6.3.3.1.Market Size Forecast
        • 6.3.3.1.1.By Value
      • 6.3.3.2.Market Share Forecast
        • 6.3.3.2.1.By Product Type
        • 6.3.3.2.2.By Target Enrichment Method
        • 6.3.3.2.3.By Target capture type
        • 6.3.3.2.4.By Application
        • 6.3.3.2.5.By End Users

7.Europe Targeted Sequencing Market Outlook

  • 7.1.Market Size Forecast
    • 7.1.1.By Value
  • 7.2.Market Share Forecast
    • 7.2.1.By Product Type
    • 7.2.2.By Target Enrichment Method
    • 7.2.3.By Target capture type
    • 7.2.4.By Application
    • 7.2.5.By End Users
    • 7.2.6.By Country
  • 7.3.Europe: Country Analysis
    • 7.3.1.France Targeted Sequencing Market Outlook
      • 7.3.1.1.Market Size Forecast
        • 7.3.1.1.1.By Value
      • 7.3.1.2.Market Share Forecast
        • 7.3.1.2.1.By Product Type
        • 7.3.1.2.2.By Target Enrichment Method
        • 7.3.1.2.3.By Target capture type
        • 7.3.1.2.4.By Application
        • 7.3.1.2.5.By End Users
    • 7.3.2.Germany Targeted Sequencing Market Outlook
      • 7.3.2.1.Market Size Forecast
        • 7.3.2.1.1.By Value
      • 7.3.2.2.Market Share Forecast
        • 7.3.2.2.1.By Product Type
        • 7.3.2.2.2.By Target Enrichment Method
        • 7.3.2.2.3.By Target capture type
        • 7.3.2.2.4.By Application
        • 7.3.2.2.5.By End Users
    • 7.3.3.United Kingdom Targeted Sequencing Market Outlook
      • 7.3.3.1.Market Size Forecast
        • 7.3.3.1.1.By Value
      • 7.3.3.2.Market Share Forecast
        • 7.3.3.2.1.By Product Type
        • 7.3.3.2.2.By Target Enrichment Method
        • 7.3.3.2.3.By Target capture type
        • 7.3.3.2.4.By Application
        • 7.3.3.2.5.By End Users
    • 7.3.4.Italy Targeted Sequencing Market Outlook
      • 7.3.4.1.Market Size Forecast
        • 7.3.4.1.1.By Value
      • 7.3.4.2.Market Share Forecast
        • 7.3.4.2.1.By Product Type
        • 7.3.4.2.2.By Target Enrichment Method
        • 7.3.4.2.3.By Target capture type
        • 7.3.4.2.4.By Application
        • 7.3.4.2.5.By End Users
    • 7.3.5.Spain Targeted Sequencing Market Outlook
      • 7.3.5.1.Market Size Forecast
        • 7.3.5.1.1.By Value
      • 7.3.5.2.Market Share Forecast
        • 7.3.5.2.1.By Product Type
        • 7.3.5.2.2.By Target Enrichment Method
        • 7.3.5.2.3.By Target capture type
        • 7.3.5.2.4.By Application
        • 7.3.5.2.5.By End Users

8.Asia-Pacific Targeted Sequencing Market Outlook

  • 8.1.Market Size Forecast
    • 8.1.1.By Value
  • 8.2.Market Share Forecast
    • 8.2.1.By Product Type
    • 8.2.2.By Target Enrichment Method
    • 8.2.3.By Target capture type
    • 8.2.4.By Application
    • 8.2.5.By End Users
    • 8.2.6.By Country
  • 8.3.Asia-Pacific: Country Analysis
    • 8.3.1.China Targeted Sequencing Market Outlook
      • 8.3.1.1.Market Size Forecast
        • 8.3.1.1.1.By Value
      • 8.3.1.2.Market Share Forecast
        • 8.3.1.2.1.By Product Type
        • 8.3.1.2.2.By Target Enrichment Method
        • 8.3.1.2.3.By Target capture type
        • 8.3.1.2.4.By Application
        • 8.3.1.2.5.By End Users
    • 8.3.2.India Targeted Sequencing Market Outlook
      • 8.3.2.1.Market Size Forecast
        • 8.3.2.1.1.By Value
      • 8.3.2.2.Market Share Forecast
        • 8.3.2.2.1.By Product Type
        • 8.3.2.2.2.By Target Enrichment Method
        • 8.3.2.2.3.By Target capture type
        • 8.3.2.2.4.By Application
        • 8.3.2.2.5.By End Users
    • 8.3.3.South Korea Targeted Sequencing Market Outlook
      • 8.3.3.1.Market Size Forecast
        • 8.3.3.1.1.By Value
      • 8.3.3.2.Market Share Forecast
        • 8.3.3.2.1.By Product Type
        • 8.3.3.2.2.By Target Enrichment Method
        • 8.3.3.2.3.By Target capture type
        • 8.3.3.2.4.By Application
        • 8.3.3.2.5.By End Users
    • 8.3.4.Japan Targeted Sequencing Market Outlook
      • 8.3.4.1.Market Size Forecast
        • 8.3.4.1.1.By Value
      • 8.3.4.2.Market Share Forecast
        • 8.3.4.2.1.By Product Type
        • 8.3.4.2.2.By Target Enrichment Method
        • 8.3.4.2.3.By Target capture type
        • 8.3.4.2.4.By Application
        • 8.3.4.2.5.By End Users
    • 8.3.5.Australia Targeted Sequencing Market Outlook
      • 8.3.5.1.Market Size Forecast
        • 8.3.5.1.1.By Value
      • 8.3.5.2.Market Share Forecast
        • 8.3.5.2.1.By Product Type
        • 8.3.5.2.2.By Target Enrichment Method
        • 8.3.5.2.3.By Target capture type
        • 8.3.5.2.4.By Application
        • 8.3.5.2.5.By End Users

9.South America Targeted Sequencing Market Outlook

  • 9.1.Market Size Forecast
    • 9.1.1.By Value
  • 9.2.Market Share Forecast
    • 9.2.1.By Product Type
    • 9.2.2.By Target Enrichment Method
    • 9.2.3.By Target capture type
    • 9.2.4.By Application
    • 9.2.5.By End Users
    • 9.2.6.By Country
  • 9.3.South America: Country Analysis
    • 9.3.1.Brazil Targeted Sequencing Market Outlook
      • 9.3.1.1.Market Size Forecast
        • 9.3.1.1.1.By Value
      • 9.3.1.2.Market Share Forecast
        • 9.3.1.2.1.By Product Type
        • 9.3.1.2.2.By Target Enrichment Method
        • 9.3.1.2.3.By Target capture type
        • 9.3.1.2.4.By Application
        • 9.3.1.2.5.By End Users
    • 9.3.2.Argentina Targeted Sequencing Market Outlook
      • 9.3.2.1.Market Size Forecast
        • 9.3.2.1.1.By Value
      • 9.3.2.2.Market Share Forecast
        • 9.3.2.2.1.By Product Type
        • 9.3.2.2.2.By Target Enrichment Method
        • 9.3.2.2.3.By Target capture type
        • 9.3.2.2.4.By Application
        • 9.3.2.2.5.By End Users
    • 9.3.3.Colombia Targeted Sequencing Market Outlook
      • 9.3.3.1.Market Size Forecast
        • 9.3.3.1.1.By Value
      • 9.3.3.2.Market Share Forecast
        • 9.3.3.2.1.By Product Type
        • 9.3.3.2.2.By Target Enrichment Method
        • 9.3.3.2.3.By Target capture type
        • 9.3.3.2.4.By Application
        • 9.3.3.2.5.By End Users

10.Middle East and Africa Targeted Sequencing Market Outlook

  • 10.1.Market Size Forecast
    • 10.1.1.By Value
  • 10.2.Market Share Forecast
    • 10.2.1.By Product Type
    • 10.2.2.By Target Enrichment Method
    • 10.2.3.By Target capture type
    • 10.2.4.By Application
    • 10.2.5.By End Users
    • 10.2.6.By Country
  • 10.3.MEA: Country Analysis
    • 10.3.1.South Africa Targeted Sequencing Market Outlook
      • 10.3.1.1.Market Size Forecast
        • 10.3.1.1.1.By Value
      • 10.3.1.2.Market Share Forecast
        • 10.3.1.2.1.By Product Type
        • 10.3.1.2.2.By Target Enrichment Method
        • 10.3.1.2.3.By Target capture type
        • 10.3.1.2.4.By Application
        • 10.3.1.2.5.By End Users
    • 10.3.2.Saudi Arabia Targeted Sequencing Market Outlook
      • 10.3.2.1.Market Size Forecast
        • 10.3.2.1.1.By Value
      • 10.3.2.2.Market Share Forecast
        • 10.3.2.2.1.By Product Type
        • 10.3.2.2.2.By Target Enrichment Method
        • 10.3.2.2.3.By Target capture type
        • 10.3.2.2.4.By Application
        • 10.3.2.2.5.By End Users
    • 10.3.3.UAE Targeted Sequencing Market Outlook
      • 10.3.3.1.Market Size Forecast
        • 10.3.3.1.1.By Value
      • 10.3.3.2.Market Share Forecast
        • 10.3.3.2.1.By Product Type
        • 10.3.3.2.2.By Target Enrichment Method
        • 10.3.3.2.3.By Target capture type
        • 10.3.3.2.4.By Application
        • 10.3.3.2.5.By End Users

11.Market Dynamics

  • 11.1.Drivers
  • 11.2.Challenges

12.Market Trends Developments

  • 12.1.Merger Acquisition (If Any)
  • 12.2.Product Launches (If Any)
  • 12.3.Recent Developments

13.Porters Five Forces Analysis

  • 13.1.Competition in the Industry
  • 13.2.Potential of New Entrants
  • 13.3.Power of Suppliers
  • 13.4.Power of Customers
  • 13.5.Threat of Substitute Products

14.Competitive Landscape

  • 14.1.MGI Tech Co., Ltd
    • 14.1.1.Business Overview
    • 14.1.2.Company Snapshot
    • 14.1.3.Products Services
    • 14.1.4.Financials (As Reported)
    • 14.1.5.Recent Developments
    • 14.1.6.Key Personnel Details
    • 14.1.7.SWOT Analysis
  • 14.2.GENEWIZ Inc
  • 14.3.Agilent Technologies, Inc.
  • 14.4.Daicel Arbor Biosciences
  • 14.5.Danaher Corporation
  • 14.6.Illumina, Inc.
  • 14.7.LGC Biosearch Technologies
  • 14.8.Pacific Biosciences of California Inc
  • 14.9.CD Genomics
  • 14.10.F. Hoffmann-La Roche Ltd

15.Strategic Recommendations

16.About Us Disclaimer